Switching of hypertrophic signalling towards enhanced cardiomyocyte identity and maturity by a GATA4-targeted

Lotta Pohjolainen1, Sini M Kinnunen1, Samuli Auno2

  • 1Drug Research Program and Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, 00014, Helsinki, Finland.

PubMed

Insights

A novel compound, 3i-1262, promotes the maturation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). This compound modulates cardiac transcription factors, enhancing cardiomyocyte identity and maturity for potential heart failure treatments.

Area of Science:

  • Cardiovascular Research
  • Stem Cell Biology
  • Drug Discovery

Background:

  • Increasing heart failure prevalence necessitates novel therapeutic strategies.
  • Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are valuable in vitro models but exhibit immaturity.
  • Immature hiPSC-CMs resemble fetal cardiomyocytes, limiting their utility for studying adult heart conditions.

Purpose of the Study:

  • To develop and screen novel compounds for their ability to modulate cardiac function.
  • To investigate the effects of a lead compound on cardiomyocyte hypertrophy and maturation.
  • To understand the molecular mechanisms underlying compound-induced changes in hiPSC-CMs.

Main Methods:

  • Synthesis and screening of 14 novel compounds for GATA4-NKX2-5 reporter activity and toxicity.
  • Selection of compound 3i-1262 for further studies on induced hypertrophy models.
  • Assessment of morphological changes, protein expression, and gene expression using immunofluorescence, high-content analysis, qPCR, and RNA sequencing.

Main Results:

  • Compound 3i-1262 inhibited GATA4-NKX2-5 synergy and reduced the hypertrophy biomarker B-type natriuretic peptide (BNP).
  • 3i-1262 treatment increased metabolic activity and cardiac troponin T expression in hiPSC-CMs.
  • RNA sequencing revealed that 3i-1262 promotes gene expression related to metabolic activity and cell cycle exit, indicating enhanced maturity.

Conclusions:

  • Compound 3i-1262 effectively promotes hiPSC-CM maturation by reorganizing the cardiac transcription factor network.
  • This approach converts hypertrophic signaling towards enhanced cardiomyocyte identity and maturity.
  • The compound provides a novel scaffold for developing therapies to improve cardiomyocyte specification and maturity.
Abstract